Form 4: Humacyte Director Amends SEC Filing to Correct Common Stock Sale Reporting

Humacyte, Inc. Director and 10% Owner Brady W. Dougan has filed an amended Form 4 with the SEC to correct a previous reporting error regarding the sale of 510,161 shares of common stock.

Summary

• Brady W. Dougan, a Director and 10% Owner of Humacyte, Inc. (HUMA), filed an amended Form 4 on June 16, 2025.
• The amendment corrects an error in a Form 4 filed on August 21, 2023, which incorrectly reported the sale of 510,161 shares of Humacyte common stock by Ayabudge LLC.
• The corrected filing clarifies that these 510,161 shares were sold directly by Brady W. Dougan, not by Ayabudge LLC.
• Following the reported transaction and correction, Brady W. Dougan's beneficial ownership of common stock is 0 shares directly, 2,241,045 shares indirectly through Ayabudge LLC, 243,851 shares indirectly by spouse, and 1,148,240 shares indirectly through The Niklason Living Trust.
• The filing also details 80,000 stock options with an exercise price of $2.41, granted on June 12, 2025, which will vest over time.
• The first 25% of these options become exercisable on June 12, 2026, with the remaining portion vesting monthly (1/48) through June 12, 2029, and expiring on June 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an error in a previous filing is a minor negative, the act of promptly correcting it demonstrates transparency and adherence to regulatory requirements, which is a positive for corporate governance.

Positives

• The filing demonstrates transparency and commitment to accurate reporting by correcting a previous error.
• Clarifies the direct ownership and transaction history of a significant insider.

Negatives

• An error in a previous SEC filing indicates a potential lapse in initial reporting accuracy.

Risks

• Minor risk of misinterpretation or confusion due to the need for an amendment to correct past reporting.

Future Outlook

Brady W. Dougan's 80,000 stock options, granted on June 12, 2025, are set to vest over a period of four years. The first 25% will become exercisable on June 12, 2026, with the remainder vesting monthly (1/48) until June 12, 2029. These options will expire on June 12, 2035.

Industry Context

This filing is a routine insider transaction report and amendment, specific to Humacyte, Inc. and its director. It does not directly reflect broader industry trends but underscores the ongoing regulatory requirements for transparency in insider holdings within the biotechnology or medical device sector.

Related Party Transactions

• The filing clarifies beneficial ownership through Ayabudge LLC, an entity controlled by the Reporting Person, and through a spouse and a living trust, indicating related party holdings.

Stakeholder Impact

• Shareholders: Provides clearer and more accurate information regarding the beneficial ownership of a key director and 10% owner, enhancing transparency.
• Regulatory Authorities: Demonstrates compliance with SEC reporting requirements by correcting a previous error.

Next Steps

• The stock options granted to Brady W. Dougan will begin vesting, with the first 25% becoming exercisable on June 12, 2026.
• Subsequent vesting will occur monthly (1/48) through June 12, 2029.

Key Dates

Keywords

Humacyte, HUMA, SEC Form 4, Insider Trading, Beneficial Ownership, Stock Options, Amendment, Corporate Governance, Director, Equity Securities